SACHI BIOWORKS, INC.

Lousiville, CO · Biotech · Private

Human organoid development and therapeutic screening platform using microgravity in space

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: Lousiville, CO
Total capital: $10.4M

Federal grants: $586K; 3 awards · 2022–2023; Rank in peer group#21 of 48
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $9.8M; 4 awards · NASA; Rank in Biotech#60 of 4373
Granted patents: 2; 6 pending · first 2022; Rank in peer group#6 of 48

Capital timeline

Latest events

Mar 2024Federal contractNASA · SBIR Phase III - Reversing Immune Dysregulation During Spaceflight Missions$2.2M
Jul 2023Federal contractNASA · E014042 SBIR Phase III Rapid, Low-cost Nanoligomertm Based Drug-discovery In Space$5.4M
Feb 2023Federal grantHealth and Human S · Phase I · Novel Nanoligomer-Based Therapeutics for Inflammatory Bowel Disease$55K
Sep 2022Federal grantHealth and Human S · Phase I · Novel Nanoligomer-Based Therapeutics for Inflammatory Bowel Disease$365K
Jul 2022Federal grantNASA · Phase I · Rapid, Low-Cost Drug-Discovery in Space$166K
Apr 2022Federal contractNASA · E014042 SBIR Phase II Reversing Immune Dysregulation During Spaceflight Missions$2M
May 2021Federal contractNASA · Fast Technology For Reversing Immune Dysregulation During Spaceflight Missions$131K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 48 peers

Line = median

Biotech · Platform

Federal grants#21 · top 44%
Granted patents#6 · top 13%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 2 granted of 8

May 26, 2026GrantedComposition Of A Therapeutic OligomerUSPTOUS 12,636,303
May 9, 2024PendingMethods And Systems For Targeting Autoimmune And Inflammatory Pathways Using NanoligomersUSPTOApplication 18376197
Dec 21, 2023PendingMethods And Systems For Targeting Autoimmune And Inflammatory Pathways Using NanoligomersUSPTOApplication 18137101

Show all 8 patent records

Composition Of A Therapeutic OligomerMay 26, 2026 · US 12,636,303Granted
Methods And Systems For Targeting Autoimmune And Inflammatory Pathways Using NanoligomersMay 9, 2024 · Application 18376197Pending
Methods And Systems For Targeting Autoimmune And Inflammatory Pathways Using NanoligomersDec 21, 2023 · Application 18137101Pending
System And Method For Producing A Therapeutic OligomerDec 20, 2022 · US 11,530,406Granted
Method For Mitigating A Viral Agent Infection In A Subject And System For Biodistributing A Nanoligomer In A SubjectApplication 63390909Pending
Oligomer For Mitigation Of Neuroinflammatory Disease, And A Method For Manufacturing The SameApplication 63344152Pending
Methods And Systems For Reversing Radiation-induced ImmunosuppressionApplication 63335485Pending
Methods And Systems For Targeting Neuroinflammatory Pathways Using NanoligomersApplication 63409294Pending

ProteoPrinceps, LLCShares a founder: PRASHANT NAGPAL, DUNS:117489668
Twist BioscienceSimilar federal contract value in Biotech · $12M in contracts
Codagenix Inc.Similar federal contract value in Biotech · $11.2M in contracts
Ceramedix Holding, LLCSimilar federal contract value in Biotech · $10.2M in contracts
INNOVATION PATHWAYS, LLCSimilar federal contract value in Biotech · $9.2M in contracts
Noveome Biotherapeutics, Inc.Similar federal contract value in Biotech · $8.5M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.